Currently, domestic phase III clinical trials of HPGDS inhibitors are underway to assess the efficacy and safety of these inhibitors for DMD pathologies, using the inhibition of limb muscle weakness and atrophy in DMD patients as indicators (NCT04587908/jRCT2041200055) [33,34]. Here, HPGDS is linked to Duchenne muscular dystrophy.